Event-Driven Stocks

Impax Laboratories, LLC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 2 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY17FY16FY15FY14FY13FY12
Revenue$184.4M$225.5M$143.1M$118.7M$511.5M$581.7M
Operating income−$402.7M−$494.2M$69.6M$88.8M−$6.4M$83.0M
Net income−$98.4M−$10.4M−$6.3M$6.4M$101.3M$55.9M
Total assets$1.35B$1.82B$1.92B$1.08B$996.9M$864.0M
Total liabilities$1.16B$1.20B$860.1M$191.3M$186.7M$172.9M
Equity$187.2M$624.0M$1.06B$887.9M$810.2M$691.1M
EPS (diluted)$-1.37$-0.15$-0.09$0.09$1.47$0.82
Shares out.73.7M72.6M71.3M69.7M68.5M66.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2017
Operating margin
−218.4%
Net margin
−53.4%
Return on equity
−52.6%
Return on assets
−7.3%
Return on capital (ROCE)
−40.4%
Liabilities / assets
86.1%
Debt / equity
6.22×
Book value / share
$2.54
Revenue growth (YoY)
−18.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2017
Altman Z″ (distress)
-1.08distress
Accruals / assets
−13.5%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
37
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 100Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.